Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MC5R | P33032 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | MC1R | Q01726 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 4/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.37 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861006 | 1.00 | ANPEP (0.40) | ANPEPRNPEPDNPEPMC4RMC5R | |
| SCHEMBL1673135 | 0.87 | MC4R (0.38) | MC4RMC5RMC3RMC1RNPY4R | |
| SCHEMBL27797839 | 0.87 | MC4R (0.38) | MC4RMC5RMC3RMC1RNPY4R | |
| SCHEMBL537112 | 0.85 | ANPEP (0.36) | ANPEPRNPEPDNPEPMC4RMC5R | |
| SCHEMBL28896045 | 0.84 | MMP9 (0.41) | MC4RMC5RMC3RMC1REPHX2 | |
| SCHEMBL7642635 | 0.83 | MC4R (0.42) | ANPEPRNPEPDNPEPMC4RMC5R | |
| SCHEMBL27913206 | 0.79 | ANPEP (0.43) | ANPEPRNPEPDNPEPNPY4RNPY1R | |
| SCHEMBL27913200 | 0.79 | ANPEP (0.43) | ANPEPRNPEPDNPEPNPY4RNPY1R | |
| Arginine SCHEMBL14861498 | 0.78 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPNPY4RNPY1R | |
| Arginine SCHEMBL4795238 | 0.78 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2765999-A1 | INGESTIBLE MULTI-SHEET UNIT HAVING PREDETERMINED FUNCTIONS AND COMBINATIONS | Purdue Research Foundation (US) | 2014-08-20 | — | — | EP | claimed |
| WO-2013056213-A1 | INGESTIBLE MULTI-SHEET UNIT HAVING PREDETERMINED FUNCTIONS AND COMBINATIONS | PURDUE RESEARCH FOUNDATION (US) | 2013-04-18 | — | — | WO | claimed |
| EP-4716741-A2 | COMPOSITIONS AND METHODS FOR REDUCING CXCL9, CXCL10, AND CXCL11 GENE EXPRESSION | Flagship Labs 114, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250352669-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCERS BY MODULATING THE EXPRESSION AND/OR ACTIVITY OF STUB1 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4580648-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCERS BY MODULATING THE EXPRESSION AND/OR ACTIVITY OF STUB1 | President and Fellows of Harvard College (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12290543-B1 | Bioavailable compositions comprising cannabinoids and cyclodextrins | SCHANEVILLE SCOTT (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2024243438-A2 | COMPOSITIONS AND METHODS FOR REDUCING CXCL9, CXCL10, AND CXCL11 GENE EXPRESSION | OMEGA THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240344061-A1 | COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSION | OMEGA THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | US | disclosed |
| US-20240254462-A1 | COMPOSITIONS AND METHODS FOR MODULATING SECRETED FRIZZLED RECEPTOR PROTEIN 1 (SFRP1) GENE EXPRESSION | OMEGA THERAPEUTICS, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240207341-A1 | INGESTIBLE FILMS HAVING SUBSTANCES FROM HEMP OR CANNABIS | SCHANEVILLE SCOTT (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207340-A1 | INGESTIBLE FILMS HAVING SUBSTANCES FROM HEMP OR CANNABIS | SCHANEVILLE SCOTT (US) | 2024-06-27 | — | — | US | disclosed |
| US-20210236465-A1 | METHODS AND COMPOSITIONS FOR TREATING HETEROTOPIC OSSIFICATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-05 | — | — | US | disclosed |
| WO-2021061815-A1 | COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4α) GENE EXPRESSION | OMEGA THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021061707-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | OMEGA THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-3510152-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | Flagship Pioneering, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018049077-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049079-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049075-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049073-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-6251869-B1 | SUCH AS L-PHENYLALANYL-L-ARGINYL-BETA-NAPHTHYLAMIDE; FOR TREATING GRAM-NEGATIVE ORGANISMS INFECTIONS IN MAMMALS | PHARMACIA & UPJOHN COMPANY | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12290543-B1 | Bioavailable compositions comprising cannabinoids and cyclodextrins | CNR1, CNR2, SI | ANPEP 4731/4885RNPEP 4793/4885DNPEP 4505/4885 |
| US-20240207340-A1 | INGESTIBLE FILMS HAVING SUBSTANCES FROM HEMP OR CANNABIS | CNR1, CNR2, SI | ANPEP 4534/4885RNPEP 4636/4885DNPEP 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.